Böcking A, Chatelain R, Auffermann W, Löhr G W, Reif M, Rossner R, Becker H
Anticancer Res. 1986 Sep-Oct;6(5):1217-23.
The clinical significance of the DNA-malignancy grade (DNA-MG) was tested in 90 malignant lymphoma patients. Feulgen stained imprint smears from freshly cut lymph-nodes were investigated. DNA measurements were performed using various cytophotometers. The scalar DNA-MG, ranging from 0.1 to 3.0, was calculated from the variance of the tumor cells around the 2c peak. Except for the CLL, all entities of the Kiel classification for non-Hodgkin's malignant lymphomas showed considerable variation of the DNA-MGs. The DNA-MG, the age of the patients and the response to treatment were seen to have a significant influence on the survival time of non-Hodgkin's lymphoma patients. In high grade lymphoma patients of the Kiel classification, the DNA-MG was found to provide additional prognostic information. The DNA-MG was strongly correlated with the ESR, low albumin concentration, low lymphocyte counts in peripheral blood, clinical and pathological staging, and the response to treatment.
在90例恶性淋巴瘤患者中检测了DNA恶性程度分级（DNA-MG）的临床意义。研究了新鲜切割淋巴结的福尔根染色印片涂片。使用各种细胞光度计进行DNA测量。标量DNA-MG范围为0.1至3.0，由肿瘤细胞围绕2c峰的方差计算得出。除慢性淋巴细胞白血病（CLL）外，非霍奇金恶性淋巴瘤的基尔分类中的所有实体的DNA-MG均显示出相当大的差异。DNA-MG、患者年龄和对治疗的反应被认为对非霍奇金淋巴瘤患者的生存时间有显著影响。在基尔分类的高级别淋巴瘤患者中，发现DNA-MG可提供额外的预后信息。DNA-MG与红细胞沉降率（ESR）、低白蛋白浓度、外周血淋巴细胞计数低、临床和病理分期以及对治疗的反应密切相关。
